ET80 Stock Chart & Stats
€4.44
€0.20(4.34%)
At close: 4:00 PM EDT
€4.44
€0.20(4.34%)
Day’s Range― - ―
52-Week Range€1.49 - €7.89
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€5.63M
Enterprise Value€1.56M
Total Cash (Recent Filing)€5.27M
Total Debt (Recent Filing)€1.95M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.03
Shares Outstanding996,394
10 Day Avg. Volume1
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Operating MetricsThe combination of renewed TTM revenue growth and a higher gross margin indicates operating performance is moving in a better direction after the 2025 decline. If maintained, this stabilization can improve product economics and provide a firmer base for future scale.
Narrowing LossesLosses have narrowed substantially from 2024 and 2025 to the latest TTM period, showing meaningful progress in cost control or operating efficiency. Continued improvement would reduce the funding burden and move the company closer to sustainable earnings, although it has not reached profitability.
Conservative LeverageThe relatively low debt-to-equity ratio gives COSCIENS a more conservative capital structure and reduces the immediate burden of interest and refinancing obligations. This financial flexibility can help the company manage ongoing development needs while it works to improve profitability and cash generation.
Bears Say
Persistent UnprofitabilityDespite substantial improvement in the size of its losses, COSCIENS remains deeply unprofitable, with a negative net margin and deeply negative return on equity. Persistent earnings losses limit internally generated capital, weaken shareholder returns, and leave profitability dependent on further operating progress.
Continued Cash BurnNegative operating and free cash flow show that the business is still consuming cash rather than funding itself. Although operating outflows improved versus earlier periods, the sharp TTM decline in free cash flow keeps financing requirements and balance-sheet execution risk relevant over the next several quarters.
Modest Revenue GrowthThe latest revenue stabilization is positive, but growth remains modest and follows a prior annual decline. Limited top-line expansion can constrain operating leverage, slow the path toward breakeven, and make it harder for improved gross margins to offset the company’s still substantial cost base.
COSCIENS Biopharma News
ET80 FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was €1.49 and its highest was €7.89 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is €5.63M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Nov 17, 2026 which is in 19 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on Aug 11, 2026. The company reported -€0.171 earnings per share for the quarter.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 996,394 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -€0.171 in its last earnings report. Following the earnings report the stock price went up 5.329%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in DE:ET80
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―